Story perspectives

Eli Lilly Buys AtaiBeckley for $3.8 B, Securing Psychedelic Depression Drug

7/23/2026

Summary

Lilly Acquires AtaiBeckley

Eli Lilly announced on July 16, 2026 it will acquire AtaiBeckley for $3.8 billion, paying $2.8 billion cash upfront and $1 billion in milestones.
The deal targets BPL-003, a 5-MeO-DMT nasal spray in Phase 3 for depression that earned FDA Breakthrough Therapy Designation after a Phase 2a trial showed a 66.7 % response by day two.
Analysts project $1-$2 billion annual sales, making the $3.8 billion purchase the sector’s biggest—above AbbVie’s $1.2 billion Gilgamesh deal—as Lilly diversifies beyond its GLP-1 portfolio.

Summary

Lilly Under Review

A House committee is reviewing Eli Lilly’s China trials, adding political scrutiny to its rapid acquisitions.
On July 13, 2026 the Department of Health and Human Services (HHS) and Veterans Affairs (VA) signed a pact to speed veteran psychedelic research.
The FDA issued guidance the same day, reinforcing support for fast-acting psychedelic drug development.
An April 2026 executive order to fast-track Breakthrough Therapy reviews underpinned Lilly’s $2.8 billion upfront commitment, shaping trial approvals and policy.

History

Historical Context

In 2020 the FDA granted Breakthrough Therapy Designation—the first for a psychedelic—to MAPS’s MDMA-assisted PTSD psychotherapy, meeting criteria that a drug show improvement for a serious condition. The designation, approved for about one-third of 100 CDER requests, enabled a 2021 Phase 3 trial of 90 veterans funded by the VA and paved the way for Lilly’s 2026 $3.8 billion acquisition of AtaiBeckley, expanding investment in psychedelic medicine.

1 of 3

Lilly Acquires AtaiBeckley

Eli Lilly announced on July 16, 2026 it will acquire AtaiBeckley for $3.8 billion, paying $2.8 billion cash upfront and $1 billion in milestones.
The deal targets BPL-003, a 5-MeO-DMT nasal spray in Phase 3 for depression that earned FDA Breakthrough Therapy Designation after a Phase 2a trial showed a 66.7 % response by day two.
Analysts project $1-$2 billion annual sales, making the $3.8 billion purchase the sector’s biggest—above AbbVie’s $1.2 billion Gilgamesh deal—as Lilly diversifies beyond its GLP-1 portfolio.

1 / 3